Kyverna Reports One-Year Autoimmune CAR-T Data, Targets BLA Completion
publishers 6articles 6first reported 24 Sep, 10:02 UTCdeveloping since 25 Sep · 2 editions
Kyverna said one-year data for its CAR-T therapy miv-cel showed durable, drug-free remission and a favorable safety profile in patients with stiff person syndrome and generalized myasthenia gravis. The company said the longer-term results support its planned FDA submission for the rare autoimmune therapy.
Kyverna is aiming to complete its biologics license application for miv-cel in stiff person syndrome this year. If approved, the treatment could become the first CAR-T therapy cleared by the FDA for an autoimmune condition.
HOW THIS STORY WAS MADE
Written from 6 articles, headlines and summaries only; 6 independent newsrooms once syndicated copies count as one; this version written 6 h after the record first saw the story; the editor kept it as written.
- Publishers
- 6
- Source articles
- 6
- Given to the writer
- 6, headlines and summaries only
- Independent newsrooms
- 6
- This version written
- 6 h after the record first saw the story
- Second model (editor)
- kept as written
- Publication gate
- passed
- Human review
- none
Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →